Dexmedetomidine as an adjuvant to bupivacain in unilateral transversus abdominis plane block in pediatrics

Dexmedetomidine as an adjuvant to bupivacaine in unilateral transversus abdominis plane block in pediatrics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201710002714125

Enrollment

Registered

2017-10-22

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery postoperative pain

Interventions

control (C)

Dexmedetomidine 0.5 ug (D0.5)

Dexmedetomidine 1ug (D1ug)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients as ASA class I or II , aged from 1-7 years old undergoing any lower abdominal surgery that requires skin incision in one side of midline of the anterior abdominal wall .

Exclusion criteria

Exclusion criteria: Participants refusing regional block and those having bleeding disorders, skin lesions or wounds at the site of proposed needle insertion, evidence of peritonitis, septicemia and hepatic disease or enlargement in addition to those who required emergency procedures or operations that requires exploratory longitudinal midline incision were excluded from the study.

Design outcomes

Primary

Measure	Time frame
compare the efficacy of two different doses of dexmedetomedine as an adjuvant to bubivacaine in unilateral TAP block in pediatric patients undergoing lower abdominal surgery	—

Secondary

Measure	Time frame
compare the safety of two different doses of dexmedetomedine as an adjuvant to bubivacaine in unilateral TAP block in pediatric patients undergoing lower abdominal surgery	—

Countries

Egypt

Contacts

Public Contacthaidy mansou

lecturer

haidy_mourad@yahoo.com01221802324

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026